Drug-target binding affinity is pivotal in determining therapeutic efficacy. AKSO Bio's proprietary DEEP protein engineering platform, enhanced with AI, not only invents biologic therapeutics with ultra-strong binding affinities in the femtomolar range but also facilitates the discovery of designer molecules for complex targets such as GPCRs through our unique liposomal-based expression system. AKSO Bio is vigorously advancing numerous in-house programs across a broad spectrum of therapeutic areas, with significant investments in autoimmune diseases, fibrosis, and oncology. Our bispecific oncology asset, AB002, has received IND clearance and is poised for clinical advancement.